The Trump administration will require drug companies to post their list prices in consumer ads under a proposal to be announced next week — a prominent part of its drug price agenda, according to four individuals with knowledge of the plan. But experts caution that the impact may be relatively insignificant and it could even confuse patients, considering the complexities of drug pricing. (Dan Diamond and Sarah Karlin-Smith, Politico)
